Overview

Thyroid Treatment Trial

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
0
Participant gender:
All
Summary
This project will compare the efficacy and safety of 2 methods of disease modification in the treatment of active moderate and severe thyroid orbitopathy. A prospective, randomized, double-blind, parallel, controlled multidisciplinary clinical trial involving Singapore National Eye Centre, National University Hospital, Changi General Hospital, Tan Tock Seng Hospital and University of British Columbia Orbital Services, Singapore Eye Research Institute, Singapore General Hospital Endocrinology and Radiology Departments and Tan Tock Seng Hospital Rheumatology Department is planned. The SingHealth-SGH High Field MR Research Laboratory will be involved in the MR imaging of the trial patients. Patients who satisfy the inclusion and exclusion criteria will be asked to participate in this trial. After informed consent (Appendix B) is obtained, each patient will be randomized into one of two treatment arms: 1) Intravenous high-dose pulsed methylprednisolone (1 gram infusion over 1 hour per day with a total of 3 doses over 3 days; 4 cycles at 6 weekly intervals) and oral placebo and 2) Intravenous high-dose pulsed methylprednisolone (same dose) plus oral methotrexate 7.5 mg per week for 2 weeks, increased to 10 mg per week for another 2 weeks then 12.5 mg per week for 5 months (total 6 months of methotrexate treatment). Depending on patient response, the dose can be further increased by 2.5mg per week every 4 weeks to a maximum of 20 mg per week. A strict management protocol will be observed for each recruited patient. Patients who develop adverse side effects or need for surgical intervention will receive appropriate treatment (i.e. treatment will deviate from the protocol but will continue to be monitored). Patients who refuse treatment will be observed clinically and with imaging as a natural control group until such time as intervention is accepted. The patients will have a baseline assessment followed by regular visits to assess treatment response and adverse effects. Observations will include the use of an inflammatory index, motility measurements including quantitative ductions, exophthalmometry readings, palpebral aperture readings and indices of optic nerve function. With regards to the imaging, the patients will be assessed with an initial quantitative CT scan and 3-Tesla MRI scan prior to treatment. After treatment is started, patients will also undergo repeat MRI scan at 24 weeks and 72 weeks to assess quantitative changes with treatment using the Muscle Diameter Index (MDI) and Pixel Value Ratio (PVR) for the inferior rectus, superior rectus, the medial rectus, lateral rectus and orbital fat (Appendix E). Serum and urine will be obtained at the same time intervals as the MRI scan to assess levels of thyroid hormones, thyroid antibodies and urinary glycosaminoglycans (GAGs). Free T4, free T3 and TSH will be recorded to monitor control of hyperthyroidism. Thyroid antibodies measured will include thyroid stimulating immunoglobulin (TSI), thyrotropin-binding inhibition antibody (TB II), thyroid peroxidase antibodies and thyroglobulin antibody. Other tests including the full blood count, urea and electrolytes will be run prior to each dose of steroid treatment and during follow-up to monitor for adverse effects. The results of the assessments will be analyzed for significant differences in treatment response between the 2 groups. The indices of interest will include the percentage of patients in each group who demonstrate a decrease in the inflammatory index of at least 2 points and the time taken for 50% of patients to show such a decrease. Other parameters that reflect the visual function and motility will be compared at different points in time after starting treatment to observe response and sustainability of response. From the serial MRI scans, quantitative analysis of orbital tissues will be done to identify changes with treatment. Antibody and GAG levels will be analyzed to detect any change with treatment. The types and frequency of adverse side effects in the 2 groups will also be assessed. 80 normal subjects will be recruited for MRI scan of the orbits and brain to obtain normative values for the MDI and PVR for the Asian population (Appendix E). This will include 20 subjects from each of 4 decades (21-30 years, 31-40 years, 41-50 years, 51-60 years). The normative data will also be used to create a virtual orbital atlas. This aspect of the study will be performed in collaboration with the Labs for Information Technology (A-Star).
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Singapore National Eye Centre
Collaborator:
International Stem Cell Forum
Treatments:
Methotrexate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Criteria
Inclusion Criteria:

1. Confirmed TED (as defined by Bartley and Gorman19)

- Eyelid retraction (upper eyelid margin at or above the superior corneoscleral limbus
in primary gaze without frontalis muscle contraction) in association with any one of
the following:

- Thyroid dysfunction or abnormal regulation (increased serum thyroxine or
triiodothyronine level, decreased serum thyroid stimulating hormone level,
absence of thyroid radioiodine uptake suppression after administration of
triiodothyronine, or the presence of thyroid stimulating immunoglobulins in
serum)

- Exophthalmos (Hertel measurement of at least 20mm)

- Extraocular muscle involvement (restrictive myopathy or objective evidence of
enlarged muscles)

- Optic nerve dysfunction (abnormal visual acuity, colour vision, pupillary
reaction or perimetry not attributable to other causes)

OR

- Thyroid dysfunction or abnormal regulation in association with any one of the
following:

-Exophthalmos

- Extraocular muscle involvement

- Optic nerve dysfunction

2. Active disease

Inflammatory Index

Inflammatory Index

Soft tissue feature Rating Chemosis 0 Absent

1. Moderate (up to lid margin)

2. Severe (over lid margin; persists on closing eye)

Conjunctival injection 0 Absent 1 Present

Lid injection 0 Absent

1 Present

Lid edema 0 Absent

1. Moderate

2. Severe (festoons, overhang)

Pain at rest (clearly defined as retrobulbar aching) 0 Absent 1 Present

Pain on movement 0 Absent

1 Present

Total possible 8

Active disease is defined as an inflammatory index of at least 3 together with acute or
subacute onset (3 months and under) and/or evidence of progression (from history or
clinical observation).

(3) Moderate or severe disease

Primary Criteria

Mild Moderate Severe Inflammatory Index <3 3-5 >5

Motility <1/3 1/3 to 2/3 >2/3 (involving any one muscle) limitation limitation Limitation

Elevation, depression, adduction and abduction of the individual eyes will be measured with
a modified Aimarck perimeter with input from both patient and the orthoptist who performs
the test 20.

Secondary Criteria 21,22,23,24

Mild Moderate Severe Exophthalmos (mm) <21 21-24 25 or more

Best corrected vision (Logmar) - - 0.6 or worse

CT criterion (Muscle Diameter Index) 21-24 25-30 31 and above

These criteria are not considered absolutes and emphasize measurable indices based on
previous studies.

The presence of at least 1 primary criterion and at least 1 secondary criterion places the
patient in the more advanced disease group (in the situation where 1 primary criterion is
mild and the other severe, the presence of 1 severe secondary criterion will yield a severe
grade whereas absence of this criterion will result in a mild grade) eg 1) a patient with
an inflammatory index of 6 and moderate limitation of extraocular motility, 21mm proptosis,
0.3 vision and MDI of 26 has moderate disease as the secondary criteria for severe disease
was not present eg 2) a patient with an inflammatory index of 5 and mild limitation of
extraocular motility, 21mm proptosis, 0.3 vision and MDI of 30 has moderate disease as 1
primary and 2 secondary criteria for moderate disease were present eg 3) a patient with
inflammatory index of 6 and mild limitation of extraocular motility, 20mm proptosis, 0.3
vision and MDI of 21 has mild disease as the secondary criterion for severe disease was
absent and the other primary parameter (motility) was graded mild.

(4) Age between 21 - 60

(5) Written informed consent is obtained

Exclusion Criteria:

1. Previous treatment for TED

- Oral steroids (e.g. immunosuppressive dose) for last 3 months, radiotherapy

- Intravenous pulsed steroid or methrotrexate therapy

2. Medically unfit to receive I/V high-dose pulsed methylprednisolone or methotrexate

- History of cardiac arrthymias, recent acute myocardial infarction

- History of seizure

- History of acute bleeding peptic ulcer

- History of pulmonary tuberculosis, Hepatitis B carrier, Hepatitis C positivity,
HIV

- Uncontrolled diabetes or hypertension (to be eligible for the trial, random blood
glucose must be < 11.1 mmol/L and blood pressure must be 140/90 or lower#. If
above these limits, patients can be treated and reviewed at 2 weeks for enrolment
when criteria are met - provided the patient does not have optic neuropathy)

- Hepatic dysfunction (Alb, AST, ALT and Alkaline phosphates levels must be within
normal range for eligibility)

- Renal impairment (Urea and Creatinine levels must be within normal range)

- Abnormal blood count (outside normal range)

3. Others

- Fertile females considering becoming pregnant during the course of the study and
those not willing to take precautions to avoid pregnancy

- Both female and male planning to start a family during the trial period or within
6 months of stopping the drugs

- History of seizure

- History of mental / psychiatric disorder

- Patients with clinical features of optic nerve disc pallor at primary
presentation will be excluded